MG-LZ8™
Scientific Evidence
Five independent laboratories. Eight years of continuous analytical documentation. One extract — independently verified at every level of the quality chain.
Species Identity &
Genomic Confirmation
Species confirmed as Ganoderma sichuanense Zhao & Zhang (= G. lingzhi) by independent genomic sequencing
Inqaba Biotechnical Industries (Pty) Ltd conducted dual-marker ITS and EF1-alpha sequencing of the MG-LZ8™ source culture. ITS region: 99.69% identity match. EF1-alpha region: 100% identity match. GenBank accession numbers OR685549.1 (ITS) and JX029974.1 (EF1-alpha) provide independently verifiable links to deposited reference sequences at NCBI.
| Marker | Identity Match | GenBank Accession | Species Confirmed |
|---|---|---|---|
| ITS Region | 99.69% | OR685549.1 | G. sichuanense (= G. lingzhi) |
| EF1-alpha Region | 100% | JX029974.1 | G. sichuanense (= G. lingzhi) |
The same analysis confirmed a commercially available product from a high-profile international mycology supplier as Ganoderma sessile — a taxonomically distinct North American species — misidentified as G. lucidum in that product’s labelling.
Pre-Clinical
Immunological Validation
Significant immune activation confirmed with zero cytotoxicity
Prof. Vaclav Větvěrka, Department of Pathology, University of Louisville, Kentucky USA — one of the world’s leading researchers in immunological beta-glucan science with over 300 published studies — conducted an independent pre-clinical trial of MG-LZ8™ in 2018.
At 100 μg/ml: IL-2 cytokine increased from 1.1 pg/ml to 262.4 pg/ml (238-fold) at 24 hours. Phagocytosing neutrophils increased from 31.1% baseline to 47.2% (+51.7%) at 24 hours. Cytotoxicity assessment at 48 hours: zero cytotoxic effect on all four cancer cell lines at all doses tested.
Compound Profile &
Comparative Analysis
Antler extract 12:1 MG-LZ8™ compared to the world’s 16:1 benchmark conk extract: 48.8% total integration advantage. GA/B compound: 57-fold advantage. This sets the world’s first Antler benchmark, which is now in a category of its own.
A direct comparative LC-MS/QTOF analysis was conducted at the Central Analytical Facility (CAF), Stellenbosch University — instrument operator Prof. Marietjie Stander; report compiled by Dr. T. Little, Raluka Biotech — placing MG-LZ8™ alongside the 16:1 conk extract under identical analytical conditions.
MG-LZ8™ total integration: 109,072 units. 16:1 conk extract total integration: 73,325 units. Overall advantage: 48.8%. The GA/B compound (RT 32.17) was detected at 8.07% in MG-LZ8™ versus 0.14% in conk extract — a 57-fold differential.
| Compound | Conk Benchmark 16:1 (%) | MG-LZ8™ (%) | Differential |
|---|---|---|---|
| Ganoderic Acid A (GA) | 17.73 | 16.13 | -- |
| Ganoderic Acid B (GB) | 7.00 | 8.40 | MG-LZ8™ +20% |
| Ganoderic Acid D (GD) | 11.00 | 8.68 | -- |
| 12-Acetoxyganoderic Acid F | 8.81 | 6.97 | -- |
| Ganoderenic Acid B (GEB) | 9.75 | 5.29 | -- |
| DHTLO | 5.66 | 7.05 | MG-LZ8™ +25% |
| Ganoderic Acid C2 (GC2) | 4.97 | 6.03 | MG-LZ8™ +21% |
| GA/B (RT 32.17) — Antler-specific marker | 0.14 | 8.07 | MG-LZ8™ 57× higher |
| Unknown (RT 28.5) | 3.91 | 5.51 | MG-LZ8™ +41% |
| Unknown (RT 25.84) | Not detected | 3.07 | MG-LZ8™ only |
MG-LZ8™ full triterpenoid spectrum vs two detectable peaks in registered SA pharmaceutical Reishi product
A separate LC-MS/QTOF analysis compared MG-LZ8™ against a commercially available Reishi product from a registered South African pharmaceutical supplier. MG-LZ8™ produced a rich, well-resolved chromatographic profile with 11 specific triterpenoid compounds identified. The comparator product produced two detectable peaks.
β-Glucan
Quantification
β-glucan confirmed at 9.10% w/w (as-is basis) in MG-LZ8™ finished extract by Megazyme K-YBGL assay
The Neogen/Megazyme K-YBGL assay was applied to MG-LZ8™ finished extract (sample H23-25401). At 9.10% beta-glucan in a 15mg capsule, MG-LZ8™ delivers 1.37mg beta-glucan per dose. The same run confirmed the 16:1 conk extract at 20.31% beta-glucan. A second Megazyme test is required to complete the MG-LZ8™ glucan profile expected to be at 25% or more due to two other adulterated samples that were submitted for comparison.
Purity, Safety
& Heavy Metals
Starch below detection limit. Heavy metals compliant. Zero pathogens confirmed.
SANAS-accredited laboratory Mérieux NutriSciences (accreditation T0350) conducted a full purity and safety analysis of MG-LZ8™ in October 2023.
| Parameter | Result | Limit / Significance |
|---|---|---|
| Starch | <0.50g/100g (below detection) | Confirms zero grain substrate contamination |
| Total fat | 25.6g/100g | Confirms intact lipid-soluble triterpenoid fraction |
| Glycaemic carbohydrates | 2.71g/100g (glucose only) | Confirms absence of starch-derived carbohydrate load |
| E. coli, S. aureus, Salmonella | Zero detected | Full pathogen panel clear |
Heavy metals confirmed well below international limits at raw material stage
| Heavy Metal | Result | International Limit | Margin |
|---|---|---|---|
| Lead | 0.171 ppm | <3.0 ppm | 17.5× below limit |
| Cadmium | 0.018 ppm | <1.0 ppm | 55× below limit |
| Mercury | 0.002 ppm | <0.10 ppm | 50× below limit |
Extraction Methodology
& Consistency
29× extraction multiplier confirmed by independent HPLC. 12× antler morphology advantage confirmed by expert chromatographic interpretation.
Verve Dynamics Laboratory (R.P. Davies, Somerset West) conducted independent HPLC comparative analysis in July 2017. The ethanolic extract showed a 29-fold increase in total triterpenoid content compared to raw antler material. Expert chromatographic interpretation of the antler vs standard conk comparison identified approximately a 12-fold triterpenoid concentration advantage for the antler form.
Combined cascade: 12 × 29 = 348×
One 15mg capsule of MG-LZ8™ delivers the active compound equivalent of approximately 5,220mg of standard imported Reishi powder.
The 12× and 29× are independent, compounding advantages: 12× is a powder-to-powder morphological comparison (Antler vs conk); 29× is the extraction multiplier applied to that superior starting material.
In-house extraction profile confirmed identical to original Verve Dynamics validated baseline
Following technology transfer and in-house extraction implementation, Ecogreen Analytics (Gregory Ondrejkovic) independently verified that the current MG-LZ8™ in-house extraction profile matches the original Verve Dynamics validated profile. This confirms that the 348× concentration cascade is maintained across production batches under in-house conditions.
Independent Academic Validation
of Cultivation Methodology
Mushroom Guru antler cultivation protocol independently reproduced and confirmed under academic supervision at University of the Free State
Miss. C. Van der Berg, under the supervision of Prof. B.C. Viljoen (Department of Microbial, Biochemical and Food Biotechnology, University of the Free State), conducted a formal academic study of Ganoderma lucidum industrial and medicinal applications. The Mushroom Guru G. lucidum tissue culture (UFS-GL1) was used as the founding culture.
The Mushroom Guru elevated CO₂ antler induction protocol was independently reproduced under controlled academic conditions. Antler formation was confirmed within 28 days.
Mr C. Fourie (2015) — Craig Fourie’s prior research on lignocellulosic substrate conversion via Ganoderma mycelium — is cited as primary academic literature within the thesis. This constitutes formal academic citation of Mushroom Guru’s founder as an independent scientific source.
Five-Laboratory
Verification Summary
| Laboratory | Key Finding | Date |
|---|---|---|
| Verve Dynamics (R.P. Davies) Somerset West, South Africa | 12× antler morphology triterpenoid advantage confirmed. 29× extraction cascade confirmed by HPLC. Dual-phase CoAs issued with full heavy metals and microbiological panels. | July 2017 |
| Stellenbosch University CAF Prof. Marietjie Stander (instrument operator); Dr. T. Little, Raluka Biotech (report compiler) | 11 specific triterpenoid compounds identified. Head-to-head vs Global conk benchmark: 48.8% total integration advantage. GA/B compound: 57-fold advantage. Comparator pharmaceutical product: two detectable peaks. | May & Oct 2021 |
| Mérieux NutriSciences SANAS-accredited T0350 | Starch below detection limit. Heavy metals compliant. Zero pathogens. Full nutritional profile confirming intact lipid-soluble triterpenoid fraction. | Oct 2023 |
| Neogen / Megazyme K-YBGL | β-glucan confirmed at 9.10% w/w (as-is basis) using industry-standard K-YBGL method. Same run confirmed conk benchmark at 20.31% and detected a 75% maltodextrin adulteration in a South African comparator “extract” sample. South Africa needs a strong regulatory institution to keep “fake” products off the store shelf. | Oct 2023 |
| Inqaba Biotechnical Industries Pretoria, South Africa | Species identity confirmed as G. sichuanense Zhao & Zhang (= G. lingzhi). ITS: 99.69%. EF1-alpha: 100%. GenBank accessions OR685549.1 and JX029974.1. This is the most ancient strain of Ganoderma lingzhi. Previously, Mushroom Guru assumed their strain to be Ganoderma lucidum. This shows the importance of DNA sequencing. | Aug 2025 |
| Ecogreen Analytics Gregory Ondrejkovic | In-house extraction confirmed an improvement to original Verve Dynamics 40:1 validated profile in 2017. Extraction consistency has been maintained across multiple batches to confirm a successful technology transfer from Verve Dynamics to Mushroom Guru. MG-LZ8™ is now created at the Mushroom Guru (GMP ready) facility in Strand. | Feb 2025 |
The Antler
Developmental Biology
The antler is not a stress response — it is the mushroom’s natural exploration state, activated by a single environmental signal
Ganoderma sichuanense carries two fully encoded developmental programs in its genome. Which one runs is determined by a single environmental signal: the ratio of CO₂ to oxygen in the immediate atmosphere.
When CO₂ is elevated — as it is underground, inside decaying wood, or in a sealed cultivation environment — the organism activates its exploration program. It grows vertically, elongating and sending structures upward to find oxygen. The reproductive program is held in reserve.
The moment oxygen is detected as the growing tip reaches open air, the signal reverses. The antler program is downregulated. The pileus begins to form, spore production begins, and the organism transitions from exploration to reproduction.
Elevated CO₂ signal active. Organism growing vertically toward oxygen. Full secondary metabolite biosynthesis running. Ganoderic acids, triterpenoids, LZ-8 protein at peak concentration. Reproductive switch held in reserve.
Oxygen signal received. Antler program downregulated. Pileus formation begins. Biological resources redirected from secondary metabolite production to spore production and reproduction. Triterpenoid density falls.
Mushroom Guru harvests exclusively at the antler stage — before the oxygen signal reverses the developmental program.
Glyconutrient Profile --
The Communication Layer
MG-LZ8™ contains five of the eight essential saccharides required for immune cell communication — confirmed by independent MS/QTOF and nutritional analysis
Research by Dr. Steve Nugent identified eight monosaccharides required for the glycoprotein structures on cell surfaces that govern immune cell-to-cell communication. Modern diets typically provide only two of these eight.
Mannose and fucose are of particular immunological significance. Mannose engages the mannose receptor CD206 on macrophages and dendritic cells. Fucose is a key component of the selectin-ligand structures that govern immune cell migration and tissue homing.
The LZ-8 immunomodulatory protein — the first mushroom immune protein ever characterised, isolated from Ganoderma — has a structure with functional homology to the Fc domain of human immunoglobulins.
Clinical Translation --
What the Data Means in Practice
Laboratory numbers translated into clinical and formulation relevance
| Laboratory Finding | Clinical / Formulation Relevance |
|---|---|
| IL-2 238-fold increase at 24 hours (Větvěrka, 2018) | IL-2 is the primary cytokine governing T-cell proliferation and immune surveillance. A 238-fold increase signals robust adaptive immune activation. Relevant for practitioners working with immunocompromised patients, post-viral recovery, and oncology support protocols where T-cell function is the clinical target. |
| Phagocytosing neutrophils +51.7% at 24 hours | Neutrophils are the first-responder cell population. A +51.7% activation increase at 24 hours means faster, more effective innate response. Clinically relevant for infection recovery, wound healing, and any condition where innate immune clearance is the rate-limiting factor. |
| Zero cytotoxicity on four cancer cell lines at all doses | Safety confirmation for practitioners working with oncology patients. Immune activation without cytotoxic effect means the compound stimulates the immune system through signalling pathways rather than direct cellular toxicity. |
| Starch below detection limit. Zero pathogens. | For formulators: clean label calculations, no hidden carbohydrate load. For practitioners: safe for patients on low-carbohydrate or grain-free protocols. |
| 15mg dose — 348× concentration cascade | For formulators: 585mg+ of capsule space remains after a full therapeutic MG-LZ8™ dose in a standard size 00 capsule. No other Reishi ingredient on the SA market offers this formulation flexibility at validated therapeutic equivalence. |
| GA/B compound — 57-fold advantage vs NAMMEX. Not identified in published literature. | A high-abundance unidentified compound represents active scientific discovery. For pharmaceutical partners: a research opportunity. For practitioners: evidence that the antler morphology produces a categorically different compound profile. |
| Five saccharides confirmed — including mannose and fucose | Mannose engages CD206 on macrophages and dendritic cells. Fucose supports selectin-ligand structures governing immune cell migration. Both absent from most supplement formats. |
Note for Oncology Practitioners
MG-LZ8™ has been repositioned as a licensed 90-day clinical protocol for post-treatment immune restoration. The specific clinical hypothesis — that MG-LZ8™’s neutrophil activation capacity supports MPO-mediated clearance of carbon-based nanocarriers used in oncological drug delivery — is the subject of a proposed clinical trial at Stellenbosch University and Tygerberg Academic Hospital. Practitioners working in this space are invited to make contact directly.
Analytical documentation, sample quantities, and practitioner pricing available on request.
MG-LZ8™ is selective about the formulations and protocols it enters.
Request documentation or samples
Original laboratory reports, sample quantities, practitioner pricing, and formulator briefs available to authorised practitioners, formulators, and regulatory parties on request.
Request documentation or samples →All data on this page is sourced from original third-party laboratory reports held on file by Mushroom Guru (Pty) Ltd. All referenced test results were produced by independent, accredited, or university-affiliated laboratories. Original source documents are available to authorised practitioners, formulators, and regulatory parties on request.
This page does not constitute a medical claim. MG-LZ8™ is a validated bioactive extract under ongoing scientific investigation. This medicine has not been evaluated by SAHPRA. This medicine is not intended to diagnose, treat, cure or prevent any disease.
32 years cultivation experience | 13 years Ganoderma sichuanense cultivation and dual-phase extraction refinement
Mushroom Guru (Pty) Ltd | Reg. 2014/075567/07 | Strand, Western Cape, South Africa
